These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 3597800)

  • 1. Mianserin pharmacokinetics and behavior in hyperkinetic children.
    Winsberg BG; Camp-Bruno JA; Vink J; Timmer CJ; Sverd J
    J Clin Psychopharmacol; 1987 Jun; 7(3):143-7. PubMed ID: 3597800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
    Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind administration of methylphenidate to mentally retarded children with attention deficit disorder; a preliminary study.
    Varley CK; Trupin EW
    Am J Ment Defic; 1982 May; 86(6):560-6. PubMed ID: 7102728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder?
    Waschbusch DA; Pelham WE; Waxmonsky J; Johnston C
    J Dev Behav Pediatr; 2009 Apr; 30(2):158-68. PubMed ID: 19363369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal dosages of methylphenidate for improving the learning and behavior of hyperactive children.
    Charles L; Schain R; Zelniker T
    J Dev Behav Pediatr; 1981 Sep; 2(3):78-81. PubMed ID: 7188579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
    J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.
    Secnik K; Matza LS; Cottrell S; Edgell E; Tilden D; Mannix S
    Med Decis Making; 2005; 25(1):56-70. PubMed ID: 15673582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of attention deficit-hyperactivity disorder in children with nonmonosymptomatic nocturnal enuresis: a 4-year followup study.
    Baeyens D; Roeyers H; Van Erdeghem S; Hoebeke P; Vande Walle J
    J Urol; 2007 Dec; 178(6):2616-20. PubMed ID: 17945295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive validity of ICD-10 hyperkinetic disorder relative to DSM-IV attention-deficit/hyperactivity disorder among younger children.
    Lahey BB; Pelham WE; Chronis A; Massetti G; Kipp H; Ehrhardt A; Lee SS
    J Child Psychol Psychiatry; 2006 May; 47(5):472-9. PubMed ID: 16671930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-regulation of slow cortical potentials: a new treatment for children with attention-deficit/hyperactivity disorder.
    Strehl U; Leins U; Goth G; Klinger C; Hinterberger T; Birbaumer N
    Pediatrics; 2006 Nov; 118(5):e1530-40. PubMed ID: 17060480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced salivary cortisol in children with comorbid Attention deficit hyperactivity disorder and oppositional defiant disorder.
    Kariyawasam SH; Zaw F; Handley SL
    Neuro Endocrinol Lett; 2002 Feb; 23(1):45-8. PubMed ID: 11880861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.